# Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)

> **NCT01755624** · PHASE2 · UNKNOWN · sponsor: **NovoCure Ltd.** · enrollment: 18 (actual)

## Conditions studied

- 1-5 Brain Metastases From Non-Small Cell Lung Cancer

## Interventions

- **DEVICE:** NovoTTF-100A device
- **OTHER:** Best Standard of Care

## Key facts

- **NCT ID:** NCT01755624
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755624, "Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01755624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*